San Francisco, Calif., 13 October, 2010 - Elsevier Business Intelligence, publisher of PharmAsia News, IN VIVO and "The Pink Sheet," today announced the agenda for Windhover's 2nd PharmAsia Summit (Oct. 25-26). This year's Summit will bring top biopharma leaders from Asia and the U.S. to San Francisco to share what works and what doesn't in China, India, Japan and the Pacific Rim.
At the PharmAsia Summit, you'll hear Asia strategies and case studies from industry leading experts on dealmaking, commercial strategy, outsourcing, regulatory risks, IP protection, and pricing and reimbursement. Confirmed speakers include:
- Biogen Idec's Gunther Winkler, Senior VP Asia Pacific & Global Government Strategy
- Merck's Ramesh Subrahmanian, Senior VP & President of Asia Pacific Human Health
- Takeda Research Investment CEO Graeme Martin
- Pfizer's Neil Gibson, CSO Oncology Research
- Gilead's Clifford Samuel, VP International Access
- Advinus Therapeutics CEO Rashmi Barbhaiya
- Onyx CEO Anthony Coles
- S*Bio CEO Jan-Anders Karlsson
- Piramal Life Sciences Managing Director Somesh Sharma
- IMS Asia Pacific VP Jan Willem Eleveld
- Piper Jaffrey China Healthcare Analyst Hongbo Lu
Plus, you'll have a rare opportunity to speak with top Asia regulators, including:
- U.S. FDA China Office Director Chris Hickey
- U.S. FDA India Office Director Bruce Ross
- Shanghai FDA Deputy Director General Yi Chengdong
- Korea FDA's Hong Soon-Wook, Director Pharmaceutical Safety Policy
"PharmAsia Summit is a rare opportunity for U.S. biopharma execs to gain an insider's perspective on the most important developments in China, India and Japan without having to cross the Pacific," said Gerry Stoia, president of Elsevier Business Intelligence. "Given the increasing importance of markets like China and India to the biopharma industry, we are honored to host this distinguished group in San Francisco, and hope the Summit will contribute to the dialogue between U.S. and Asia biopharma leaders."
Attendees will in addition learn the latest on China healthcare reform, U.S. FDA actions in China and India, case studies on Japanese dealmaking with U.S. biotechs, novel Asia investment strategies, tips for launching innovative therapies in India and China, opportunities for pre-competitive collaboration that will help de-risk R&D, and finding the right partner in Asia.
Moreover, attendees will catch up on the latest Asian market trends and data from IMS Health, which sees China becoming the third largest pharma market in 2011 and predicts explosive growth in other hot Asia markets like India and Korea.